Artificial Blood Vessels Market Size, Share, and Industry Analysis By Application (Aortic Diseases, Peripheral Artery Diseases, and Hemodialysis), By Material (Polytetrafluoroethylene, Polyester, and Others), By End User (Hospitals & ASCs and Specialty Cardiac Clinics & Others), and Regional Forecast 2024-2032

Artificial blood vessels are utilized to replace damaged blood vessels caused by aneurysms and bypass stenosis. The causes of blood vessel aneurysms include cardiovascular diseases such as stroke, ischemic heart disease (IHD), hypertension, and others. Thus, an increase in the prevalence of cardiovascular diseases and hypertension is expected to fuel the demand for artificial blood vessels, in turn driving the market growth. The artificial blood vessel is made of various materials including polyethene terephthalate fiber (Dacron) or polytetrafluoroethylene fiber (Teflon), polyester, elastomer, and others. These artificial blood vessels mimic the activity of natural blood vessels and attach to the body similar to a normal vessel during surgical procedures.

In addition, artificial blood vessels are required for coronary artery bypass grafting (CABG) when the availability of suitable autologous conduits is limited. The ideal cardiovascular bypass graft requires a broad range of characteristics, including strength, viscoelasticity, biocompatibility, blood compatibility and biostability. Thus, a rise in the number of cardiovascular surgeries, such as coronary artery bypass grafting (CABG), is expected to fuel the demand for artificial blood vessels in turn supplementing the growth of the market.

• For instance, as per a report published by the National Library of Medicine in August 2023, around 400,000 coronary artery bypass grafting (CABG) surgeries are performed in the U.S. every year.

However, the high cost of cardiovascular surgeries and artificial blood vessels is expected to hamper the growth of the market to a certain extent. For instance, according to an article published in June 2022, the average cost of coronary artery bypass grafting (CABG) is USD 75,368 which includes hospital as well as physician and surgeon costs.

The COVID-19 pandemic had a negative impact on the global artificial blood vessels market. It significantly affected health care and, in particular, surgical volume due to restrictions on movement. Owing to the redistribution of resources in many countries toward critical care services for patients suffering from COVID-19, cardiac surgical procedures were delayed. As a result, there has been a significant decrease in cardiac surgeries performed during the pandemic.

For instance, as per a report shared by the Journal of Cardiothoracic Surgery in March 2021, the global survey spanning 60 cardiac surgery centers identified that cardiac surgery reduced by 50–75% during the pandemic, with a more than 50% reduction in dedicated cardiac theatre rooms and ICU beds. This factor contributed to the reduced demand for artificial blood vessels and restrained the growth of the artificial blood vessels market during the COVID-19 pandemic.

Key Insights

The report covers the following key insights:

• Prevalence of Cardiovascular Diseases - by Key Countries/Regions, 2023


• Number of Cardiac Surgeries - by Key Countries/Regions, 2023


• New Product Launches, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Market

Segmentation

Analysis by Material

Based on material, the polytetrafluoroethylene segment accounted for a significant proportion of the global artificial blood vessels market in 2023. The growth was mainly attributed to the wide availability of a large number of products manufactured from polytetrafluoroethylene material and a rise in the number of product approvals for artificial blood vessels manufactured using this material. In addition, the strong focus of major market players on receiving regulatory approvals for polytetrafluoroethylene artificial blood vessels and the advantages associated with it are anticipated to further boost the segment growth. Advantages of polytetrafluoroethylene such as enhanced chemical resistance and a very low coefficient of friction, is expected to boost the adoption of polytetrafluoroethylene artificial blood vessels by surgeons, in turn propelling the growth of the segment.

• For instance, in September 2022, Medtronic received a CE mark for the first balloon-expandable covered stent indicated for chimney endovascular aneurysm repair. The Endurant II/IIs stent graft and radiant covered stent provide a standardized, completely off-label, off-the-shelf solution for short-necked juxtarenal abdominal aortic aneurysms (AAAs). It enables safe and effective endovascular repair for both urgent and elective adjacent AAA cases with a combination of proven devices supported by clinical results.

Regional Analysis

North America dominated the artificial blood vessels market in 2023 and is projected to continue its dominance over the forecast period. The growth is mainly anticipated to the increasing prevalence of cardiovascular diseases and the increasing availability of technologically advanced artificial blood vessels by market players in North America.

• For instance, as per a report shared by the Center for Disease Control and Prevention (CDC) in May 2023, about 805,000 people in the U.S. have had a heart attack. Of these, 605,000 had a first heart attack and 200,000 happened to people who have already had a heart attack.

Thus, a rise in the prevalence of heart attacks is expected to boost the demand for treatment options which is attributed to drive the growth of the market. In addition, an upsurge in the number of product approvals of artificial blood vessels in U.S. and a rise in the number of cardiovascular surgeries is expected to drive the demand for artificial blood vessels in North America.

The Asia Pacific market for artificial blood vessels is expected to grow at a significant rate over the forecast period. Factors such as a sharp rise in number of people suffering from cardiovascular diseases and hypertension and an increasing number cardiovascular surgeries is anticipated to fuel the demand for artificial blood vessels. For instance, according to an article published in April 2023, the number of cardiac procedures performed in India are estimated to be around 300,000 per year.

Key Players Covered

The report includes the profiles of key players such as Becton, Dickinson and Company, B. Braun SE, Terumo Medical Corporation, Cook Medical, Humacyte, Gore Medical, Le Maitre, Artivion, and Medtronic.

Key Industry Developments

• In July 2023, Terumo Aortic announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) granted approval of the Thoraflex Hybrid Frozen Elephant Trunk (FET) device for commercial sale in Japan for the treatment of patients with complex aortic arch disease.


• In June 2023, Cook Medical announced that the U.S. FDA approved the clinical study of Zenith Fenestrated+ Endovascular Graft for the treatment of aortic aneurysms.


• In January 2023, Medtronic announced the first patient enrollment in the advance trial, a head-to-head randomized controlled trial of two leading aortic stent graft systems, the Medtronic Endurant II/IIs stent graft system and GORE Excluder AAA Device Family systems.

In March 2022, Cook Medical announced that the Zenith Thoraco+ Endovascular System (Thoraco+) received U.S. Food and Drug Administration (FDA) approval. Thoraco+ endovascular grafts are used for the treatment of thoraco abdominal aortic aneurysms.